We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

RHINOSECTAN®

0

Barrier dysfunction in the nasal allergy

Ayumi Fukuoka, Tomohiro Yoshimoto

In this review, the authors describe the importance of the epithelial barrier and the relationship between TJ disruption and allergic diseases. In addition, they discuss new findings regarding the association of TJ disruption and exacerbation of allergic rhinitis induced by diesel exhaust particles. As a main conclusion the authors highlight that the protection of the epithelial barrier function might prevent or inhibit the development or exacerbation of allergic rhinitis.

Read more

Rhinosectan® Launched In Spain

We are pleased to announce the launch of Rhinosectan® in its first market, Spain. The product is commercialized under the brand Rinonet/Rhinosectan®, is distributed by Laboratorios SALVAT S.A.and has been available as 15 ml solution for intranasal application in pharmacies across Spain since May.

Read more

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Núria Piqué, María del Carmen Gómez-Guillén and María Pilar Montero

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.

Read more

Let's meet in..

2018, May 26

EAACI 2018

Read more

2018, May 28

PharmaVenue May 2018

Read more

2018, Jun 11

EuroPLX 67

Read more

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more

2018, Oct 24

UEG Week 2018

Read more